Coherus_Logo_RGB_150.png
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
27 nov. 2024 16h01 HE | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare...
Coherus Logo - R@2x.png
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
06 déc. 2023 04h00 HE | Coherus BioSciences, Inc.
– Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses – – Data support...
Coherus Logo - R@2x.png
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
03 nov. 2023 08h30 HE | Coherus BioSciences, Inc.
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –...
Coherus Logo - R@2x.png
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
27 sept. 2023 09h10 HE | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology...
Coherus Logo - R@2x.png
Coherus Completes Surface Oncology Acquisition
08 sept. 2023 09h05 HE | Coherus BioSciences, Inc.
– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will...
Coherus Logo - R@2x.png
Coherus to Acquire Surface Oncology
16 juin 2023 07h01 HE | Coherus BioSciences, Inc.
– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – ...